ArticleIntensive care medicine2007
Increasing evidence that the risks of rhAPC may outweigh its benefits.
Article in Intensive care medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- How the context of reception affects the meaning of RCT evidence.Health (London, England : 1997) · 2024Trial
- APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.Critical care (London, England) · 2010Trial
- MYSM1-mediated epigenetic modification dysregulation leads to immunosuppression and secondary infections in sepsis.PLoS pathogens · 2026Article
- An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Virulence · 2014Review
- The late phase of sepsis is characterized by an increased microbiological burden and death rate.Critical care (London, England) · 2011Article
- Early antimicrobial therapy in severe sepsis and septic shock.Current infectious disease reports · 2010Article
- Saponin fraction from Astragalus membranaceus roots protects mice against polymicrobial sepsis induced by cecal ligation and puncture by inhibiting inflammation and upregulating protein C pathway.Journal of natural medicines · 2009Article
- Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.Expert opinion on investigational drugs · 2009Review
- The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.Critical care (London, England) · 2009Article
- Scientific and clinical challenges in sepsis.Current pharmaceutical design · 2009Review
- Once is not enough: clinical trials in sepsis.Intensive care medicine · 2008Article
- Editors' comments on a new trial of activated protein C for persistent septic shock.Intensive care medicine · 2008Article
- Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.Current opinion in hematology · 2008Review
- Is There NO Treatment For Severe Sepsis?The Libyan journal of medicine · 2008Article
- Potential interventions in sepsis-related acute kidney injury.Clinical journal of the American Society of Nephrology : CJASN · 2008Review
- Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions.Intensive care medicine · 2007Article
- Is there increasing evidence that the risks of rhAPC may outweigh its benefits?Intensive care medicine · 2007Article
- Year in review 2006: Critical Care--Multiple organ failure, sepsis, and shock.Critical care (London, England) · 2007Review
- Mechanisms of sepsis and insights from clinical trials.Drug discovery today. Disease mechanisms · 2007Article
- Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.Drug safety · 2007Review
Corrections and comments
- Commented on by
- Commented on by
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
17325833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.